[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.
[2] Li D, Kang J, Golas BJ, et al. Minimally invasive local therapies for liver cancer[J]. Cancer Biol Med, 2014, 11(4): 217-236. DOI: 10.7497/j.issn.20953941.2014.04.001.
[3] Buendia MA, Neuveut C. Hepatocellular carcinoma[J]. Cold Spring Harb Perspect Med, 2015, 5(2): a021444. DOI: 10.1101/cshperspect.a021444.
[4] Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations[J]. Best Pract Res Clin Gastroenterol, 2014, 28(5): 843-853. DOI: 10.1016/j.bpg.2014.07.018.
[5] Chung AS, Ferrara N. Developmental and pathological angiogenesis[J]. Annu Rev Cell Dev Biol, 2011, 27: 563-584. DOI: 10.1146/annurevcellbio092910154002.
[6] Risau W. Mechanisms of angiogenesis[J]. Nature, 1997, 386(6626): 671-674. DOI: 10.1038/386671a0.
[7] Robinson SD, Reynolds LE, Kostourou V, et al. Alphav beta3 integrin limits the contribution of neuropilin1 to vascular endothelial growth factorinduced angiogenesis[J]. J Biol Chem, 2009, 284(49): 33966-33981. DOI: 10.1074/jbc.M109.030700.
[8] Narayanan N, Su N, Bedard P. Inhibitory and stimulatory effects of fluoride on the calcium pump of cardiac sarcoplasmic reticulum[J]. Biochim Biophys Acta, 1991, 1070(5): 83-91.
[9] Plein A, Fantin A, Ruhrberg C. Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability[J]. Microcirculation, 2014, 21(4): 315-323. DOI: 10.1111/micc.12124.
[10] Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin1 in embryonic vessel formation[J]. Development, 1999, 126(21): 4895-4902.
[11] Eichmann A, Makinen T, Alitalo K. Neural guidance molecules regulate vascular remodeling and vessel navigation[J]. Genes Dev, 2005, 19(9): 1013-1021. DOI: 10.1101/gad.1305405.
[12] Staton CA, Kumar I, Reed MW, et al. Neuropilins in physiological and pathological angiogenesis[J]. J Pathol, 2007, 212(3): 237-248. DOI: 10.1002/path.2182.
[13] Bergé M, Allanic D, Bonnin P, et al. Neuropilin1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodeling[J]. J Hepatol, 2011, 55(4): 866-875. DOI: 10.1016/j.jhep.2011.01.033.
[14] He Z, TessierLavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin Ⅲ[J]. Cell, 1997, 90(4): 739-751.
[15] Zhang Y, Liu P, Jiang Y, et al. High expression of neuropilin1 associates with unfavorable clinicopathological features in hepatocellular carcinoma[J]. Pathol Oncol Res, 2016, 22(2): 367-375. DOI: 10.1007/s122530150003z.
[16] Liu Q, Xu Y, Wei S, et al. miRNA148b suppresses hepatic cancer stem cell by targeting neuropilin1[J]. Biosci Rep, 2015, 35(4). pii: e00229. DOI: 10.1042/BSR20150084.
[17] Xu J, Xia J. NRP1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo[J]. Exp Ther Med, 2013, 5(1): 150-154. DOI: 10.3892/etm.2012.803.
[18] Raskopf E, Vogt A, Decker G, et al. Combination of hypoxia and RNAinterference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms[J]. Curr Pharm Biotechnol, 2012, 13(11): 2290-2298.
[19] Elpek G. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update[J]. World J Gastroenterol, 2014, 20(23): 7260-7276. DOI: 10.3748/wjg.v20.i23.7260.
[20] Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression[J]. Hepatol Int, 2013, 7(1): 4-12. DOI: 10.1007/s1207201293912.
[21] Bergé M, Allanic D, Bonnin P, et al. Neuropilin1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodeling[J]. J Hepatol, 2011, 55(4): 866-875. DOI: 10.1016/j.jhep.2011.01.033. |